10-Q: Clarivate Reports Q3 2025 Results Amid Restructuring

Clarivate Plc reported a reduced net loss for Q3 2025, with revenues remaining flat for the quarter but declining for the nine-month period, as the company continues its Value Creation Plan and debt optimization efforts.

Summary

• Net loss for the three months ended September 30, 2025, improved to $28.3 million from $65.6 million in the prior year period.
• Revenues for the three months ended September 30, 2025, were $623.1 million, a slight increase from $622.2 million in the prior year period.
• For the nine months ended September 30, 2025, revenues decreased by 2.9% to $1,838.2 million from $1,893.7 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, improved to $204.2 million from $444.9 million in the prior year period.
• Adjusted EBITDA for the nine months ended September 30, 2025, was $747.2 million, down from $775.1 million in the prior year period, with Adjusted EBITDA margin at 40.6% compared to 40.9%.
• Free cash flow for the nine months ended September 30, 2025, decreased by 7% to $276.1 million from $298.4 million.
• Organic annualized contract value (ACV) grew 1.6% compared to September 30, 2024, primarily driven by price increases.
• Total ACV declined 3.4% to $1,542.7 million as of September 30, 2025, primarily due to the ScholarOne divestiture and product group wind-downs.
• The annual renewal rate for the nine months ended September 30, 2025, improved to 93% from 92% in the prior year period.
• The company repurchased approximately 34.8 million ordinary shares for $149.5 million during the nine months ended September 30, 2025, at an average price of $4.29 per share.
• Outstanding borrowings under notes and credit facilities were $4,441.8 million as of September 30, 2025, a reduction from $4,571.1 million as of December 31, 2024.
• Restructuring and other impairments totaled $45.9 million for the nine months ended September 30, 2025, primarily associated with the Value Creation Plan.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While revenues and Adjusted EBITDA declined for the nine-month period, the net loss significantly improved, and the company successfully reduced its overall debt. The increase in cash and improved annual renewal rate are also positive. However, ongoing restructuring costs and legal proceedings introduce some uncertainty and headwinds, preventing a higher score.

Positives

• Net loss significantly improved for both the three and nine-month periods ended September 30, 2025, compared to the prior year.
• Basic EPS improved to $(0.04) for Q3 2025 and $(0.30) for 9M 2025, indicating a reduced loss per share.
• Organic annualized contract value (ACV) grew by 1.6%, driven by new sales, improved retention, and price increases.
• The annual renewal rate improved to 93% for the nine months ended September 30, 2025, demonstrating strong customer retention.
• Long-term debt decreased to $4,419.0 million as of September 30, 2025, from $4,518.7 million at December 31, 2024, reflecting successful debt management.
• Cash and cash equivalents increased to $318.7 million as of September 30, 2025, from $295.2 million at December 31, 2024.
• The company executed a debt refinancing by issuing a new $500.0 million term loan tranche to redeem $500.0 million of Senior Secured Notes due 2026, and further redeemed an additional $100.0 million of these notes.
• Foreign currency swap transactions were used to effectively convert approximately 80% of the new term loan debt from U.S. dollars to Euro, economically reducing the interest rate by approximately 2%.

Negatives

• Total revenues for the nine months ended September 30, 2025, decreased by 2.9% compared to the prior year period.
• Adjusted EBITDA declined by 3.6% for the nine months ended September 30, 2025, and Adjusted EBITDA margin slightly decreased.
• Free cash flow decreased by 7% for the nine months ended September 30, 2025, primarily due to higher restructuring costs.
• Total ACV declined by 3.4% due to the ScholarOne divestiture and product group wind-downs, indicating a reduction in the overall value of active customer subscription agreements.
• The Intellectual Property (IP) segment experienced a revenue decrease of 1.5% and a 6.9% decline in Adjusted EBITDA for the nine-month period, primarily due to the Valipat divestiture and lower re-occurring and transactional volumes.
• The Life Sciences & Healthcare (LS&H) segment saw a revenue decrease of 5.3% and a 9.7% decline in Adjusted EBITDA for the nine-month period, mainly due to product group wind-downs and lower subscription revenues.
• Significant restructuring costs of $45.9 million were incurred for the nine months ended September 30, 2025, associated with the Value Creation Plan.

Risks

• Dependence on third parties, including public sources, for data, information, and other services.
• Increased accessibility to free or relatively inexpensive information sources.
• Ability to compete in a highly competitive industry and potential adverse effects of this competition.
• Ability to maintain high annual renewal rates.
• Ability to maintain revenues if products and services do not achieve and maintain broad market acceptance, or if unable to keep pace with or adapt to rapidly changing technology, evolving industry standards, macroeconomic market conditions, and changing regulatory requirements.
• Changes in government policy positions, including trade policy, spending priorities, or reductions in government programs, government spending, or research funding.
• The success of the Value Creation Plan.
• Loss of, or inability to attract and retain, key personnel.
• Effectiveness of business continuity plans.
• Ability to derive fully the anticipated benefits from organic growth, existing or future acquisitions, joint ventures, investments, or dispositions.
• Exposure to risk from having operations and employees in Israel.
• Exposure to risk from the international scope of operations, including potentially adverse tax consequences.
• Strength of brand and reputation.
• Level of indebtedness, which could adversely affect business, financial condition, and results of operations.
• Ability to obtain, protect, defend, or enforce intellectual property rights.
• Ability to leverage artificial intelligence technologies (AI) in products and services.
• Significant disruption in or unauthorized access to or breaches of computer systems or those of third parties, including cybersecurity or cyberattacks.
• Use of open source software in products and services.
• Ability to comply with applicable data protection and privacy laws.

Future Outlook

The company expects to incur approximately $5 million of additional restructuring costs, primarily from workforce reduction, with a majority expected in 2025, as part of its Value Creation Plan. Management believes that cash flow from operations, available cash on hand, borrowing capacity, and access to capital markets will be adequate to service debt, meet liquidity needs, and fund capital expenditures and other business plans for both the next 12 months and the foreseeable future. Future capital requirements will depend on factors such as the number of future acquisitions and the timing and extent of spending to support product development efforts.

Management Comments

• Our vision at Clarivate is to fuel the world's greatest breakthroughs by harnessing the power of human ingenuity.
• We regularly monitor organic revenue growth, annualized contract value, annual renewal rates, Adjusted EBITDA, Adjusted EBITDA margin, and Free cash flow as key performance indicators that we use to evaluate our business and trends, measure performance, prepare financial projections, and make strategic decisions.

Industry Context

The company operates in a highly competitive industry, facing challenges from increased accessibility to free or relatively inexpensive information sources. Its ability to leverage artificial intelligence technologies (AI), including generative AI, large language models (LLMs), machine learning, and other AI tools, is crucial for maintaining competitiveness and adapting to rapidly changing technology and evolving industry standards. The ongoing restructuring and divestitures reflect a strategic effort to optimize its business model and reduce operational costs in a dynamic market.

Management Changes

Legal Proceedings

• Three putative securities class action complaints were filed and consolidated in the United States District Court for the Eastern District of New York, alleging weaknesses in internal controls over financial reporting, financial reporting errors related to a 2020 business combination, and false or misleading statements regarding product quality, organic revenues, and business model changes. Motions to dismiss are currently pending.
• A separate class action was filed in Pennsylvania state court under the Securities Act of 1933, asserting claims based on substantially similar allegations regarding alleged misstatements and omissions in offering documents for two issuances of ordinary shares in June and September 2021. The court has permitted discovery on issues related to standing, with supplemental briefs and oral argument to follow.
• The company believes the claims lack merit and will vigorously defend against them, but is currently unable to estimate the reasonably possible loss or range of loss, if any.

Stakeholder Impact

• Shareholders: Impacted by share repurchases, which reduce outstanding shares, and the ongoing legal proceedings which pose an unquantified risk. The improved net loss and debt reduction could be seen positively, while revenue declines and restructuring costs are headwinds.
• Employees: Affected by the Value Creation Plan, which includes workforce reductions and severance costs.
• Customers: Impacted by product group wind-downs (e.g., ScholarOne, certain LS&H and A&G products) and potential changes in service offerings, though organic ACV growth and improved renewal rates suggest overall customer retention is strong.
• Creditors: Benefited from debt reduction and refinancing efforts, which included redeeming higher-interest notes with new term loans and using foreign currency swaps to reduce effective interest rates.

Next Steps

• Continue to implement the Value Creation Plan, with approximately $5 million of additional restructuring costs expected, primarily from workforce reduction, mostly in 2025.
• Monitor and manage the ongoing legal proceedings, vigorously defending against the securities class action complaints.
• Continue to manage debt obligations and potentially seek additional funding through public or private equity or debt financings if needed for future capital requirements, acquisitions, or product development.
• Gordon Samson will work with the Group's leadership to affect a smooth transition of responsibilities until his employment termination on December 31, 2025.

Key Dates

Recommendation

Clarivate Plc's Q3 2025 filing presents a mixed financial picture. While the company successfully reduced its net loss and managed to decrease its overall debt, the nine-month revenue and Adjusted EBITDA figures show a decline. The ongoing Value Creation Plan, including significant restructuring costs and product wind-downs, indicates a strategic pivot that is still in progress. The improved annual renewal rate and organic ACV growth are positive signs for the core business, but the unquantified risks from pending securities litigation and the impact of divestitures on total ACV warrant caution. Given the ongoing transformation, the company's ability to execute its strategic plan and navigate legal challenges will be critical. A 'hold' recommendation is appropriate as investors await clearer signs of sustained revenue growth and the full realization of benefits from the restructuring efforts, while acknowledging the improved profitability and debt management.

Keywords

Financial Reporting, SEC Filing, Quarterly Results, Revenue, Net Income, Adjusted EBITDA, Free Cash Flow, Debt Management, Share Repurchase, Restructuring, Academia & Government, Intellectual Property, Life Sciences & Healthcare, Subscription Revenue, Organic Growth, Annual Renewal Rate, Legal Proceedings, Risk Factors, Corporate Governance, Management Changes